- Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
Watch Arcutis Biotherapeutics' latest callArcutis Biotherapeutics (NASDAQ:ARQT) Q2 2026 Earnings Call · Replay · Aug 5Read the transcript of Arcutis Biotherapeutics (NASDAQ:ARQT) Q2 2026 Earnings CallArcutis Biotherapeutics' next earnings callArcutis Biotherapeutics (NASDAQ:ARQT) Q3 2026 Earnings Call · Nov 4, 2026 at 4:30 PM ESTRegister
Arcutis Biotherapeutics, Inc. on 6ix
Story so far
- Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting
- Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
- Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
Earlier from Arcutis Biotherapeutics
- Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
- Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Later from Arcutis Biotherapeutics
All Arcutis Biotherapeutics news releasesFollow Arcutis Biotherapeutics into a list and get an email when it puts out news.
Follow Arcutis Biotherapeutics